Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, dactinomycin, staurosporin, mitoguazone, and everolimus premix for oncology therapeutic segment; mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, amphotericin B, and nystatin for anti-fungal therapeutic segment; and lovastatin, pravastatin sodium, and enzymes for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
Metrics to compare | CONB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCONBPeersSector | |
---|---|---|---|---|
P/E Ratio | 53.8x | 30.5x | −0.5x | |
PEG Ratio | 7.63 | 0.30 | 0.00 | |
Price/Book | 11.0x | 4.1x | 2.6x | |
Price / LTM Sales | 16.1x | 4.5x | 3.0x | |
Upside (Analyst Target) | 11.4% | 14.6% | 55.6% | |
Fair Value Upside | Unlock | −0.2% | 10.1% | Unlock |